Journal of Bone and Mineral Research最新文献

{"title":"Ed Bd, Masthead, Comm List and TOC","authors":"","doi":"10.1002/jbmr.4602","DOIUrl":"https://doi.org/10.1002/jbmr.4602","url":null,"abstract":"","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 9","pages":"FMi-FMv"},"PeriodicalIF":6.2,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jbmr.4602","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41082084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opportunistic Screening With CT: Comparison of Phantomless BMD Calibration Methods","authors":"Stefan Bartenschlager,&nbsp;Alexander Cavallaro,&nbsp;Tobias Pogarell,&nbsp;Oliver Chaudry,&nbsp;Michael Uder,&nbsp;Sundeep Khosla,&nbsp;Georg Schett,&nbsp;Klaus Engelke","doi":"10.1002/jbmr.4917","DOIUrl":"10.1002/jbmr.4917","url":null,"abstract":"<p>Opportunistic screening is a new promising technique to identify individuals at high risk for osteoporotic fracture using computed tomography (CT) scans originally acquired for an clinical purpose unrelated to osteoporosis. In these CT scans, a calibration phantom traditionally required to convert measured CT values to bone mineral density (BMD) is missing. As an alternative, phantomless calibration has been developed. This study aimed to review the principles of four existing phantomless calibration methods and to compare their performance against the gold standard of simultaneous calibration (ΔBMD). All methods were applied to a dataset of 350 females scanned with a highly standardized CT protocol (DS1) and to a second dataset of 114 patients (38 female) from clinical routine covering a large range of CT acquisition and reconstruction parameters (DS2). Three of the phantomless calibration methods must be precalibrated with a reference dataset containing a calibration phantom. Sixty scans from DS1 and 57 from DS2 were randomly selected for this precalibration. For each phantomless calibration method first the best combination of internal reference materials (IMs) was selected. These were either air and blood or subcutaneous adipose tissue, blood, and cortical bone. In addition, for phantomless calibration a fifth method based on average calibration parameters derived from the reference dataset was applied. For DS1, ΔBMD results (mean <math>\u0000 <mrow>\u0000 <mo>±</mo>\u0000 </mrow></math> standard deviation) for the phantomless calibration methods requiring a precalibration ranged from 0.1 <math>\u0000 <mrow>\u0000 <mo>±</mo>\u0000 </mrow></math> 2.7 mg/cm³ to 2.4 <math>\u0000 <mrow>\u0000 <mo>±</mo>\u0000 </mrow></math> 3.5 mg/cm³ with similar means but significantly higher standard deviations for DS2. Performance of the phantomless calibration method, which does not require a precalibration was worse (ΔBMD DS1: 12.6 <math>\u0000 <mrow>\u0000 <mo>±</mo>\u0000 </mrow></math> 13.2 mg/cm³, DS2: 0.5 <math>\u0000 <mrow>\u0000 <mo>±</mo>\u0000 </mrow></math> 8.8 mg/cm³). In conclusion, phantomless BMD calibration performs well if precalibrated with a reference dataset. © 2023 The Authors. <i>Journal of Bone and Mineral Research</i> published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 11","pages":"1689-1699"},"PeriodicalIF":6.2,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://asbmr.onlinelibrary.wiley.com/doi/epdf/10.1002/jbmr.4917","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41090756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active Vitamin D Use and Fractures in Hemodialysis Patients: Results from the International DOPPS","authors":"Hirotaka Komaba,&nbsp;Junhui Zhao,&nbsp;Angelo Karaboyas,&nbsp;Suguru Yamamoto,&nbsp;Indranil Dasgupta,&nbsp;Mohamed Hassan,&nbsp;Li Zuo,&nbsp;Anders Christensson,&nbsp;Christian Combe,&nbsp;Bruce M. Robinson,&nbsp;Masafumi Fukagawa","doi":"10.1002/jbmr.4913","DOIUrl":"10.1002/jbmr.4913","url":null,"abstract":"<div>\u0000 \u0000 <p>Active vitamin D is commonly used to control secondary hyperparathyroidism in dialysis patients, but it is unknown whether active vitamin D directly improves bone strength, independently of its ability to suppress parathyroid hormone (PTH). We analyzed the association between the prescription of active vitamin D and incidence of any fracture and hip fracture in 41,677 in-center hemodialysis patients from 21 countries in phases 3 to 6 (2005 to 2018) of the Dialysis Outcomes and Practice Patterns Study (DOPPS). We used Cox regression, adjusted for PTH and other potential confounders, and used a per-protocol approach to censor patients at treatment switch during follow-up. We also used a facility preference approach to minimize confounding by indication. Overall, 55% of patients were prescribed active vitamin D at study enrollment. Event rates (per patient-year) were 0.024 for any fracture and 0.010 for hip fracture. The adjusted hazard ratio (95% confidence interval) comparing patients prescribed versus not prescribed active vitamin D was 1.02 (0.90 to 1.17) for any fracture and 1.00 (0.81 to 1.23) for hip fracture. In the facility preference approach, there was no difference in fracture rate between facilities with higher versus lower active vitamin D prescriptions. Thus, our results do not suggest a PTH-independent benefit of active vitamin D in fracture prevention and support the current KDIGO guideline suggesting the use of active vitamin D only in subjects with elevated or rising PTH. Further research is needed to determine the role of active vitamin D beyond PTH control. © 2023 American Society for Bone and Mineral Research (ASBMR).</p>\u0000 </div>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 11","pages":"1577-1585"},"PeriodicalIF":6.2,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10339081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syntaxin 18 Defects in Human and Zebrafish Unravel Key Roles in Early Cartilage and Bone Development","authors":"Brecht Guillemyn,&nbsp;Hanna De Saffel,&nbsp;Jan Willem Bek,&nbsp;Piyanoot Tapaneeyaphan,&nbsp;Adelbert De Clercq,&nbsp;Tamara Jarayseh,&nbsp;Sophie Debaenst,&nbsp;Andy Willaert,&nbsp;Riet De Rycke,&nbsp;Peter H Byers,&nbsp;Toon Rosseel,&nbsp;Paul Coucke,&nbsp;Bettina Blaumeiser,&nbsp;Delfien Syx,&nbsp;Fransiska Malfait,&nbsp;Sofie Symoens","doi":"10.1002/jbmr.4914","DOIUrl":"10.1002/jbmr.4914","url":null,"abstract":"<div>\u0000 \u0000 <p>SNARE proteins comprise a conserved protein family responsible for catalyzing membrane fusion during vesicle traffic. Syntaxin18 (STX18) is a poorly characterized endoplasmic reticulum (ER)-resident t-SNARE. Recently, together with TANGO1 and SLY1, its involvement was shown in ER to Golgi transport of collagen II during chondrogenesis. We report a fetus with a severe osteochondrodysplasia in whom we identified a homozygous substitution of the highly conserved p.Arg10 to Pro of STX18. CRISPR/Cas9-mediated Stx18 deficiency in zebrafish reveals a crucial role for Stx18 in cartilage and bone development. Furthermore, increased expression of multiple components of the Stx18 SNARE complex and of COPI and COPII proteins suggests that Stx18 deficiency impairs antero- and retrograde vesicular transport in the crispant <i>stx18</i> zebrafish. Taken together, our studies highlight a new candidate gene for a recessive form of osteochondrodysplasia, thereby possibly broadening the SNAREopathy phenotypic spectrum and opening new doors toward future research avenues. © 2023 American Society for Bone and Mineral Research (ASBMR).</p>\u0000 </div>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 11","pages":"1718-1730"},"PeriodicalIF":6.2,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10634608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of MicroRNAs in Adult Osteogenesis Imperfecta: The miROI Study","authors":"Alexandre Mercier-Guery,&nbsp;Marjorie Millet,&nbsp;Blandine Merle,&nbsp;Corinne Collet,&nbsp;Flora Bagouet,&nbsp;Olivier Borel,&nbsp;Elisabeth Sornay-Rendu,&nbsp;Pawel Szulc,&nbsp;Emmanuelle Vignot,&nbsp;Deborah Gensburger,&nbsp;Elisabeth Fontanges,&nbsp;Martine Croset,&nbsp;Roland Chapurlat","doi":"10.1002/jbmr.4912","DOIUrl":"10.1002/jbmr.4912","url":null,"abstract":"<p>As epigenetic regulators of gene expression, circulating micro-RiboNucleic Acids (miRNAs) have been described in several bone diseases as potential prognostic markers. The aim of our study was to identify circulating miRNAs potentially associated with the severity of osteogenesis imperfecta (OI) in three steps. We have screened by RNA sequencing for the miRNAs that were differentially expressed in sera of a small group of OI patients versus controls and then conducted a validation phase by RT-qPCR analysis of sera of a larger patient population. In the first phase of miROI, we found 79 miRNAs that were significantly differentially expressed. We therefore selected 19 of them as the most relevant. In the second phase, we were able to validate the significant overexpression of 8 miRNAs in the larger OI group. Finally, we looked for a relationship between the level of variation of the validated miRNAs and the clinical characteristics of OI. We found a significant difference in the expression of two microRNAs in those patients with dentinogenesis imperfecta. After reviewing the literature, we found 6 of the 8 miRNAs already known to have a direct action on bone homeostasis. Furthermore, the use of a miRNA-gene interaction prediction model revealed a 100% probability of interaction between 2 of the 8 confirmed miRNAs and COL1A1 and/or COL1A2. This is the first study to establish the miRNA signature in OI, showing a significant modification of miRNA expression potentially involved in the regulation of genes involved in the physiopathology of OI. © 2023 The Authors. <i>Journal of Bone and Mineral Research</i> published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 11","pages":"1665-1678"},"PeriodicalIF":6.2,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://asbmr.onlinelibrary.wiley.com/doi/epdf/10.1002/jbmr.4912","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10266100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin in the Game?","authors":"Felicia Cosman","doi":"10.1002/jbmr.4908","DOIUrl":"10.1002/jbmr.4908","url":null,"abstract":"Multiple recent studies have confirmed that osteoanabolic agents reduce fractures earlier and to a greater extent than antiresorptive agents; however, clinical use is limited by the need for injection. Multiple prior attempts at transdermal or oral delivery failed for a variety of reasons, and the lack of noninjectable anabolic regimens is one of the greatest gaps in the osteoporosis treatment armamentarium. To that end, the current issue of JBMR includes a noninferiority trial that randomized 511womenwith osteoporosis to receive 1 year of treatment with transdermal abaloparatide 300 μg/day or standard subcutaneous abaloparatide 80 μg/day, previously demonstrated to be an effective and safe osteoanabolic medication in the pivotal Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE; 6). Study participants in the new investigation were similar to those enrolled in the pivotal trial with a mean age of 69, a mean spine T-score of –2.6, a mean total hip T-score of –2.2, and 80% with a prior fracture. The transdermal product is an abaloparatide-coated microneedle array applied with a reusable applicator to affix a patch to the skin. In a prior Phase 1 study, transdermal application of 300 μg to the thigh for 5 min produced a pharmacokinetic profile similar to that seen with the standard dose of 80 μg administered subcutaneously. The thigh was chosen over the abdomen for transdermal application because of a superior pharmacokinetic profile. The primary endpoint was change in the lumbar spine bone density (BMD), and noninferiority was to be achieved with a BMD difference of ≤2% between the two regimens. Regrettably, while BMD increased in both groups, spine BMD gain with subcutaneous abaloparatide (10.9%) exceeded that for transdermal abaloparatide (7.1%) by more than the noninferiority margin. Mean increments in total hip BMD were 3.7% with subcutaneous and 2.0% with transdermal administration. Even though the transdermal regimen did not meet the noninferiority endpoint in this trial, the BMD gains in both spine and hip were substantial, indicating the efficacy of the transdermal formulation. There were several interesting observations, which remain unexplained but may have contributed to the study findings. With subcutaneous administration, the serum C-telopeptide (CTX) level increased within 1 month; in contrast, with the transdermal regimen, the CTX level declined at 1 month. Themechanism of this differential CTX response to the two regimens is unclear. Beyond 1 month, serum CTX was elevated in both groups, though the increments were higher for subcutaneous than transdermal abaloparatide throughout the year. Serum levels of the bone formation marker PINP were also higher with subcutaneous application. At 1 year, the median procollagen Type I N-propeptide (PINP) increment was 75% with subcutaneous and 53% with transdermal abaloparatide. One of the most perplexing findings was the unexpected observed difference in pharmacokinetic profiles bet","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 10","pages":"1387-1388"},"PeriodicalIF":6.2,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10286714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Added Value of High-Resolution Peripheral Quantitative Computed Tomography in Fracture Risk Prediction","authors":"Mattias Lorentzon,&nbsp;Andrew J. Burghardt","doi":"10.1002/jbmr.4909","DOIUrl":"https://doi.org/10.1002/jbmr.4909","url":null,"abstract":"Modern assessment of fracture risk in clinical practice involves both considerations of clinical risk factors and measurement of bone mineral density (BMD) using dual X-ray absorptiometry (DXA). Although DXA-derived BMD is robustly associated with fracture, with every standard deviation decrease in the femoral neck (FN) BMD increases the risk of hip fracture by two to three times, the sensitivity and specificity of FN BMD alone are insufficient. Consideration of clinical risk factors, such as previous fracture, oral glucocorticoid use, heredity, and low body mass index, used in combination with FN BMD improves model performance in clinically used risk prediction tools, such as the fracture risk assessment tool FRAX, QFracture, and the Garvan calculator. The FRAX tool has been widely implemented globally and performs well in the prediction of hip fractures, while receiver operating characteristic (ROC) curve performance is lower for the prediction of major osteoporotic fracture (MOF). Especially for any fracture and MOF, novel methods to achieve improved fracture risk prediction are warranted. It is known that bone microstructural parameters obtained by high-resolution peripheral quantitative computed tomography (HR-pQCT) predict fracture risk independently of FN BMD and clinical risk factors, but any interactions between microstructural measures and how they each contribute to fracture risk have primarily been studied using traditional methods, such as Cox regression. Indeed, leveraging the information reflected by a large number of highly correlated bone microarchitecture and strength outcomes from across multiple anatomic locations remains a significant challenge to the goal of synthesizing a fracture risk metric from HR-pQCT or similar modalities. In this issue of the JBMR, Whittier et al. present a novel fracture risk assessment tool (μFRAC) based on HR-pQCT measurement results and machine learning methodology using the random survival forest method, which assembles decision trees and provides an intuitive classification resembling clinical decision-making. In a large dataset from several cohorts of older men and women (n = 6 802), the association between incident fractures (609 incident fractures during the average 4.7-year follow-up) and HR-pQCT variables were investigated using random survival forest models. They found that in evaluations of sensitivity and specificity in predicting any incident fracture, using ROC curves, the developed μFRAC tool performed better than other models or the calculated FRAX scores for the 10-year probability of MOF. These results suggest that incorporating HR-pQCT or other methods to measure bone microstructure could improve fracture prediction in a clinical setting. The study has considerable strengths. It is one of the largest yet performed and uses a novel machine learning methodology to identify the most accurate fracture prediction model incorporating HR-pQCT data. Both full models, using all standard pa","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 9","pages":"1225-1226"},"PeriodicalIF":6.2,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41081429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversible Effects of Puberty Suppression on Bone Strength, Mass, and Body Composition in Adolescent Mice After Testosterone Therapy","authors":"Ada S. Cheung","doi":"10.1002/jbmr.4906","DOIUrl":"10.1002/jbmr.4906","url":null,"abstract":"&lt;p&gt;To the Editors:&lt;/p&gt;&lt;p&gt;Concern regarding the deleterious bone effects of puberty suppression for transgender and gender diverse (trans) youth is an issue for patients, their families, and treating clinicians. Although there is considerable variability in access across jurisdictions, there has been an increase in demand for gender-affirming care for trans youth. Pubertal suppression with gonadotropin releasing hormone antagonist or agonist (GnRHa) therapy is typically commenced in early puberty (ie, Tanner stage 2) and aims to delay pubertal progression to allow maturation of the individual until an appropriate time for possible masculinizing or feminizing gender-affirming hormone therapy. Masculinizing hormone therapy typically involves testosterone therapy in standard doses used for hypogonadal men to achieve testosterone concentrations in the typical male reference range.&lt;/p&gt;&lt;p&gt;There are few studies in humans on the impact of GnRHa on bone. Retrospective and small uncontrolled cohort studies in trans youth have shown that even prior to GnRHa, bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) may be lower than in age-matched youth.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; This is largely determined by factors such as lower body mass index, low vitamin D, suboptimal calcium intake, and lower physical activity.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; After GnRHa treatment, BMD declines, but there are also associated increases in body fat including in bone marrow adipose tissue.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; After gender-affirming hormone therapy, BMD &lt;i&gt;Z&lt;/i&gt;-scores increase but may well remain below age-matched peers.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; However, all existing studies have used DXA, which has poor precision and low correlation with fracture.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; Additionally, body fat increase with GnRHa influence photon attenuation which may artifactually underestimate BMD.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; Findings also vary depending on which reference range (male or female) is used and it is unknown whether timing of gender-affirming hormone therapy commencement matters.&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;)&lt;/sup&gt; Additionally, it is difficult to extrapolate whether such changes impact peak bone mass accrual or whether observed changes are associated with a long-term risk of bone fragility or fracture in trans youth.&lt;/p&gt;&lt;p&gt;Although methodology to precisely measure the microarchitecture or breaking strength of bones in humans is challenging, this month's issue of the &lt;i&gt;Journal of Bone and Mineral Research&lt;/i&gt; (&lt;i&gt;JBMR&lt;/i&gt;) publishes a clinically relevant translational study which overcomes many of the limitations in existing literature.&lt;/p&gt;&lt;p&gt;Mimicking the clinical treatment regimens typically used for trans boys (assigned female at birth), Dubois and colleagues&lt;sup&gt;(&lt;/sup&gt;&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/sp","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 10","pages":"1389-1390"},"PeriodicalIF":6.2,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jbmr.4906","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10227370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrocardiogram Changes Following Intravenous Bisphosphonate Infusion: A Systematic Review and Meta-Analysis","authors":"Alex Shoung,&nbsp;Nicholas Shoung,&nbsp;Rachael Hii,&nbsp;Nitesh Nerlekar,&nbsp;Peter R Ebeling,&nbsp;Alexander J Rodríguez","doi":"10.1002/jbmr.4911","DOIUrl":"10.1002/jbmr.4911","url":null,"abstract":"<p>Bisphosphonates are first-line treatments for several bone and mineral disorders. Studies have reported an increased incidence of serious atrial fibrillation in patients receiving bisphosphonates; however, uncertainty remains as to whether electrical disturbances are precipitated by bisphosphonates. We aimed to review the literature for studies reporting electrocardiogram (ECG) findings in patients receiving intravenous bisphosphonates for any indication. We searched MEDLINE and EMBASE from inception until January 14, 2023, for studies reporting ECG parameters after intravenous bisphosphonate infusion. We excluded studies that only reported atrial fibrillation. Study quality was assessed using the Newcastle-Ottawa scale. Continuous data were meta-analyzed if reported in at least two studies. Random-effects models were fitted and reported as standardized mean difference (SMD) with 95% confidence intervals (95% CIs). We found 1083 unique records, of which 11 met our inclusion and exclusion criteria. Studies had a low to low/moderate risk of bias. Six prospective cohort studies were included in the meta-analysis. Five studies used zoledronic acid, whereas one study used pamidronate. Most studies (<i>n</i> = 4) were conducted in postmenopausal women with osteoporosis, one study was conducted in patients with bone metastases, and one study in children with osteoporosis secondary to cerebral palsy. Study populations ranged from <i>n</i> = 15 to <i>n</i> = 116. Heart rate–corrected QT (QTc) was significantly longer post-infusion (SMD = 0.46 ms [95% CI 0.80 to 0.11]; <i>n</i> = 67 patients, <i>k</i> = 2 studies, <i>τ</i>² = 0). There were no differences in heart rate, P wave (maximum), P wave (minimum), P wave dispersion, PR interval, QRS duration, QTc, QTc (maximum), QTc (minimum), and QTc dispersion. The correlation between pre- and post-infusion QTc was not significant (<i>p</i> = 0.93). Overall, there is a weak association between intravenous bisphosphonate infusion and a QTc interval prolongation. However, there is insufficient evidence to support an association between intravenous bisphosphonate and any ECG variable changes, which may precipitate atrial fibrillation. © 2023 The Authors. <i>Journal of Bone and Mineral Research</i> published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 11","pages":"1679-1688"},"PeriodicalIF":6.2,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://asbmr.onlinelibrary.wiley.com/doi/epdf/10.1002/jbmr.4911","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10182419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Submitted Comment Regarding our Publication “Increased Bone Material Strength Index Is Positively Associated With the Risk of Incident Osteoporotic Fractures in Older Swedish Women”","authors":"Raju Jaiswal,&nbsp;Michail Zoulakis,&nbsp;Kristian F. Axelsson,&nbsp;Daniel Sundh,&nbsp;Henrik Litsne,&nbsp;Lisa Johansson,&nbsp;Mattias Lorentzon","doi":"10.1002/jbmr.4903","DOIUrl":"10.1002/jbmr.4903","url":null,"abstract":"our study","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":"38 10","pages":"1543-1544"},"PeriodicalIF":6.2,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10131514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}